REG - J.P. Morgan SE - Stabilisation Notice

JPMorgan Chase & CoAnnouncement

Today 10:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250521:nRSU5799Ja&default-theme=true

RNS Number : 5799J  J.P. Morgan SE  21 May 2025

21(st) May 2025

Not for distribution, directly or indirectly, in or into the United States or
any jurisdiction in which such distribution would be unlawful.

Teva Pharmaceutical Finance Netherlands IV BV / Teva Pharmaceutical Finance
Netherlands III BV

Post-stabilisation Period Announcement

Further to the pre-stabilisation period announcement dated 20th May 2025, J.P.
Morgan S E, (contact: Natalie Netter Day +442071342468) hereby gives notice
that no stabilisation (within the meaning of Article 3.2(d) of the Market
Abuse Regulation (EU/596/2014) or the rules of the Financial Conduct
Authority) was undertaken by the Stabilisation Manager(s) named below in
relation to the offer of the following securities.

 Issuer:                    Teva Pharmaceutical Finance Netherlands IV BV / Teva Pharmaceutical Finance
                            Netherlands III BV
 Guarantor (if any):        N/A
 Aggregate nominal amount:  USD 700mm 5.5yr

                            USD 500mm 7.5yr
 Description:               EUR 3yr FXD Senior Unsecured Notes

                            EUR 7yr FXD Senior Unsecured Notes

                            SEC registered

                            Listing: New York Stock Exchange
 Stabilisation Manager(s):  J.P. Morgan S.E (Stabilisation coordinator)

                            BNP Paribas (Stabilisation manager)

                            Citibank (Stabilisation manager)

                            Societe Generale (Stabilisation manager)
 Offer price:               5.5yr - 99.418%

                            7.5yr - 99.256%

 

This announcement is for information purposes only and does not constitute an
invitation or offer to underwrite, subscribe for or otherwise acquire or
dispose of any securities of the Issuer in any jurisdiction

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STAFIFEDERILFIE